Sign In
Buy CGEN
$1.62
-0.0200 (-1.22%)
At Close: Nov 17, 2025
Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
10:51am, Monday, 10'th Nov 2025
Compugen Ltd. ( CGEN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Yvonne Naughton - Head of Investor Relations & Corporate Communications Eran Ophir - CEO & Director Davi
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
09:16am, Monday, 10'th Nov 2025
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.01 per share a year ago.
Compugen Reports Third Quarter 2025 Results
07:00am, Monday, 10'th Nov 2025
COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian platform trial Enrolling patients in the U.S., Israel
Compugen to Participate in Stifel 2025 Healthcare Conference
07:00am, Tuesday, 04'th Nov 2025
HOLON, Israel , Nov. 4, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
07:00am, Monday, 27'th Oct 2025
HOLON, Israel , Oct. 27, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery
Pooled analysis supports the rationale for the ongoing MAIA-ovarian trial evaluating COM701 as maintenance therapy in the earlier setting of platinum sensitive ovarian cancer HOLON, Israel , Oct. 13,
Compugen to Present at SITC 2025
07:00am, Monday, 06'th Oct 2025
HOLON, Israel , Oct. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powere
Compugen to Present Research at the Single Cell Genomics 2025 Conference
07:00am, Monday, 08'th Sep 2025
HOLON, ISRAEL , Sept. 8, 2025 /PRNewswire/ -- Compugen Ltd.
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Thursday, 28'th Aug 2025
HOLON, Israel , Aug. 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powe
Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients
05:13am, Friday, 08'th Aug 2025
Compugen is advancing its anti-PVRIG antibody COM701 in phase 1/2 as a maintenance therapy for relapsed platinum-sensitive ovarian cancer patients, with interim data expected in 2H 2026. Positive proo
Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript
06:30am, Thursday, 07'th Aug 2025
Compugen Ltd. (NASDAQ:CGEN ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Anat Cohen-Dayag - CEO, President & Director David Silberman - Chief Financial Officer Eran
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
09:21am, Wednesday, 06'th Aug 2025
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.02 per share a year ago.
Compugen Reports Second Quarter 2025 Results
07:00am, Wednesday, 06'th Aug 2025
First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025 Pooled analysis from three previously reported Phase 1
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
07:00am, Monday, 28'th Jul 2025
HOLON, Israel , July 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery po
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
07:00am, Wednesday, 23'rd Jul 2025
HOLON, Israel , July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery
